Showing results (1-10 of 258) with videos related to
Sort By:
Pageof 26
Current Hematologic Malignancy Reports|November 9, 2019
Early Management of CMLNaranie Shanmuganathan, Timothy P HughesHematology. American Society of Hematology. Education Program|December 9, 2023
Accelerated-phase CML: de novo and transformedNaranie Shanmuganathan, Timothy P HughesBlood|November 16, 2018
Molecular monitoring in CML: how deep? How often? How should it influence therapy?Naranie Shanmuganathan, Timothy P HughesHematology. American Society of Hematology. Education Program|December 17, 2009
Monitoring disease response to tyrosine kinase inhibitor therapy in CMLTimothy P Hughes, Susan BranfordBritish Journal of Haematology|June 22, 2022
Asciminib for chronic myeloid leukaemia: Next questionsNaranie Shanmuganathan, Timothy P HughesHematology. American Society of Hematology. Education Program|December 9, 2022
Management of TKI-resistant chronic phase CMLTimothy P Hughes, Naranie ShanmuganathanCritical Reviews in Oncology/Hematology|January 12, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1Delphine Réa, Timothy P HughesSeminars in Hematology|September 30, 2010
Practical considerations for monitoring patients with chronic myeloid leukemiaSusan Branford, Timothy P HughesClinical Lymphoma & Myeloma|September 26, 2009
Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reactionTimothy P Hughes, Susan BranfordCurrent Opinion in Hematology|January 20, 2011
Mutational analysis in chronic myeloid leukemia: when and what to do?Susan Branford, Timothy P HughesPageof 26